1 day ago
AstraZeneca PLC (NYSE:AZN) is paying $600 million upfront to secure global rights to Zegfrovy from Dizal Pharmaceutical Co., Ltd, adding another targeted therapy to one of the pharmaceutical industry's largest oncology portfolios. Dizal Pharmaceutical could receive an additional $900 million if specified development, regulatory, and sales milestones are achieved, bringing the agreement's potential value to $1.5 billion. Dizal will also receive tiered royalties on the global sales of Zegfrovy.
Zegfrovy, also known as sunvozertinib, is an oral treatment approved in the United States and China for certain adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Under the agreement, AstraZeneca (NYSE:AZN) will take responsibility for the treatment's global development and commercialisation.
For AstraZeneca (NYSE:AZN) shareholders, the transaction offers an opportunity to ****** s whether another targeted lung-cancer medicine can reinforce the company's oncology leadership, or whether the price adds further execution risk to an already extensive pipeline.
The agreement strengthens AstraZeneca's (NYSE:AZN) position in a therapeutic area where it already has substantial scientific and commercial experience. The company has built a major lung-cancer business around treatments including Tagrisso, Imfinzi, and Enhertu. That existing infrastructure could help AstraZeneca (NYSE:AZN) introduce Zegfrovy to physicians and patients more efficiently than a smaller developer with a limited global presence.
Zegfrovy also addresses a specific group of patients with EGFR exon 20 insertion mutations, for whom treatment options remain limited. In the Phase III WU-KONG28 trial, Zegfrovy produced median progression-free survival of 10.3 months, compared with 7.5 months for chemotherapy. AstraZeneca (NYSE:AZN) therefore gains an approved medicine supported by late-stage comparative evidence rather than an early experimental ****** et whose clinical viability remains largely unknown.
#lung #egfr
Zegfrovy, also known as sunvozertinib, is an oral treatment approved in the United States and China for certain adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Under the agreement, AstraZeneca (NYSE:AZN) will take responsibility for the treatment's global development and commercialisation.
For AstraZeneca (NYSE:AZN) shareholders, the transaction offers an opportunity to ****** s whether another targeted lung-cancer medicine can reinforce the company's oncology leadership, or whether the price adds further execution risk to an already extensive pipeline.
The agreement strengthens AstraZeneca's (NYSE:AZN) position in a therapeutic area where it already has substantial scientific and commercial experience. The company has built a major lung-cancer business around treatments including Tagrisso, Imfinzi, and Enhertu. That existing infrastructure could help AstraZeneca (NYSE:AZN) introduce Zegfrovy to physicians and patients more efficiently than a smaller developer with a limited global presence.
Zegfrovy also addresses a specific group of patients with EGFR exon 20 insertion mutations, for whom treatment options remain limited. In the Phase III WU-KONG28 trial, Zegfrovy produced median progression-free survival of 10.3 months, compared with 7.5 months for chemotherapy. AstraZeneca (NYSE:AZN) therefore gains an approved medicine supported by late-stage comparative evidence rather than an early experimental ****** et whose clinical viability remains largely unknown.
#lung #egfr
15 days ago
Our **** ysts just identified a stock with the potential to be the next Nvidia. Tell us how you invest and we'll show you why it's our #1 pick. Tap here.
Management is executing a planned leadership transition, elevating Ryan Cohlhepp to CEO to leverage his commercial oncology experience as the company nears potential launch.
The company's strategic focus remains on the pivotal Phase III FORTIFI-HN01 study for HPV-negative head and neck cancer, which is on track for substantial enrollment by year-end.
Three-year follow-up data presented at ASCO 2026 demonstrated that TGF-beta inhibition nearly doubled overall survival versus standard of care pembrolizumab in the pivotal dose cohort.
Management attributes clinical success to the mechanistic foundation of TGF-beta inhibition, which drives deeper tumor penetration and immune cell infiltration compared to standard EGFR-directed therapies.
#management #year
Management is executing a planned leadership transition, elevating Ryan Cohlhepp to CEO to leverage his commercial oncology experience as the company nears potential launch.
The company's strategic focus remains on the pivotal Phase III FORTIFI-HN01 study for HPV-negative head and neck cancer, which is on track for substantial enrollment by year-end.
Three-year follow-up data presented at ASCO 2026 demonstrated that TGF-beta inhibition nearly doubled overall survival versus standard of care pembrolizumab in the pivotal dose cohort.
Management attributes clinical success to the mechanistic foundation of TGF-beta inhibition, which drives deeper tumor penetration and immune cell infiltration compared to standard EGFR-directed therapies.
#management #year
1 month ago
You won't need a time machine and Siegfried and Roy tickets to see Tigers in Las Vegas this year.
Missouri basketball has announced that it will play an exhibition game against UNLV on Thursday, Oct. 29, in Sin City, adding a preseason road trip to precede a nonconference schedule already packed with road and neutral site matchups.
The exhibition likely will be Missouri's final tune-up game before the official beginning of the 2026-27 season, which can begin Tuesday, Nov. 3.
Mizzou has not officially announced who it will face to open its new campaign this year, although reports have suggested the Tigers will play Cleveland State — head coach Dennis Gates' former team — at Mizzou Arena on opening day.
The first officially announced game on MU's schedule is Nov. 6 against Saint Louis at Enterprise Center in St. Louis, the first of five expected neutral-site nonconference games this coming season.
#road
Missouri basketball has announced that it will play an exhibition game against UNLV on Thursday, Oct. 29, in Sin City, adding a preseason road trip to precede a nonconference schedule already packed with road and neutral site matchups.
The exhibition likely will be Missouri's final tune-up game before the official beginning of the 2026-27 season, which can begin Tuesday, Nov. 3.
Mizzou has not officially announced who it will face to open its new campaign this year, although reports have suggested the Tigers will play Cleveland State — head coach Dennis Gates' former team — at Mizzou Arena on opening day.
The first officially announced game on MU's schedule is Nov. 6 against Saint Louis at Enterprise Center in St. Louis, the first of five expected neutral-site nonconference games this coming season.
#road
1 yr. ago
Avistone Announces Encouraging Results for Vebreltinib plus Andamertinib (PLB1004) in EGFR-mutated NSCLC with MET Amplification or Overexpression at ASCO Annual Meeting 2025 http://dlvr.it/TL5JKK
http://dlvr.it/TL5JKK
http://dlvr.it/TL5JKK
